Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 14/20 | 0.56 |
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP1 | P63208 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31144083 | 0.89 | RET (0.51) | RETSYK | |
| SCHEMBL31144029 | 0.85 | RET (0.54) | RETJAK2JAK1TYK2JAK3 | |
| SCHEMBL31144058 | 0.84 | RET (0.53) | RETJAK2JAK1TYK2JAK3 | |
| SCHEMBL31144042 | 0.84 | RET (0.53) | RETJAK2JAK1TYK2JAK3 | |
| SCHEMBL31143934 | 0.84 | MEN1 (0.48) | RET | |
| SCHEMBL31144145 | 0.83 | RET (0.44) | RETSYKJAK2JAK1TYK2 | |
| SCHEMBL31143941 | 0.83 | RET (0.55) | RETJAK2JAK1TYK2JAK3 | |
| SCHEMBL31144160 | 0.81 | RET (0.57) | RETJAK2JAK1TYK2JAK3 | |
| SCHEMBL28719910 | 0.81 | RET (0.57) | RETJAK2JAK1TYK2JAK3 | |
| Hydrochloric Acid SCHEMBL28701013 | 0.81 | RET (0.56) | RETJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113461670-B | Novel compounds as inhibitors of rearrangement kinase during transfection | 南京天印健华医药科技有限公司 | 2024-08-09 | — | — | CN | disclosed |